AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12806381
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate (6-monthly injections)
Trial: 12806381
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate (6-monthly injections)
Trial: 2053506
Drug: Bromocriptine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (15 mg daily) - simplified three-step regimen
Trial: 2053506
Drug: Bromocriptine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (15 mg daily) - standard seven-step regimen
Trial: 2053506
Drug: Bromocriptine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (15 mg daily) - both regimens
Trial: 6336981
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (CMF)
Trial: 6336981
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (CMF plus T)
Trial: 30958066
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg/kg/BM)
Trial: 25005467
Drug: IV abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV abatacept (10 mg/kg) plus methotrexate (MTX)
Trial: 21816029
Drug: RTS,S/AS01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 vaccine with booster dose of RTS,S/AS01
Trial: 21816029
Drug: RTS,S/AS01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 vaccine with control vaccine at time of booster
Trial: 21816029
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine at time of primary vaccination and booster
Trial: 19947263
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus medicine group
Trial: 18630549
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine group
Trial: 17713976
Drug: Vildagliptin 25mg
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin 25mg intravenous infusion
Trial: 15733479
Drug: Nimodipine infusion
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine infusion (20 microg.kg(‐1).h(‐1))
Trial: 15733479
Drug: Nimodipine infusion
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine infusion
Trial: 11999816
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (CA)
Trial: 11999816
Drug: Ticlopidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine plus aspirin (TA)
Trial: 7886396
Drug: L-tryptophan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-tryptophan (50 mM, pH 5.7)
Trial: 7886396
Drug: L-tryptophan and
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-tryptophan and D-tryptophan (50 mM, pH 5.7)
Trial: 2896402
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg acetylsalicylic acid
Trial: 2896402
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg acetylsalicylic acid
Trial: 9973007
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg atenolol
Trial: 27058906
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D3 supplementation (4,000 IU [100 μg] daily)
Trial: 25027749
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received all standard ICU therapies
Trial: 23022759
Drug: LMWH-nadroparin calcium
RxNorm normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH-nadroparin calcium (0.3 or 0.4 mL sc) administered 2 hours before surgery
Trial: 23022759
Drug: Nadroparin calcium
RxNorm normalized name: nadroparin calcium
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin calcium administered daily post-surgery
Trial: 12585970
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose regimen of cotrimoxazole
Trial: 12585970
Drug: Escalating dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dose regimen of cotrimoxazole starting with 75 mg/day, doubled every 48 hours
Trial: 7018361
Drug: Amiloride/Hydrochlorothiazide (A/HCTH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride/Hydrochlorothiazide (A/HCTH) combination
Trial: 24041733
Drug: Four sessions
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four sessions of birth and parent preparation in small groups
Trial: 22028163
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy for four weeks
Trial: 11174772
Drug: Patch angioplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch angioplasty
Trial: 8763180
Drug: Patch closure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch closure
Trial: 28327693
Drug: Single visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single visit treatment
Trial: 28327693
Drug: Two visits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two visits with 1-week intracanal calcium hydroxide medication
Trial: 23708174
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg and Placebo
Trial: 21513721
Drug: Single s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single s.c. injection of ghrelin under cold exposure in mice
Trial: 21513721
Drug: Four-hour intravenous
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-hour intravenous ghrelin infusion in healthy humans
Trial: 10619348
Drug: Zileuton 600
RxNorm normalized name: zileuton 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zileuton 600 mg po QID for 6 weeks
Trial: 29558784
Drug: Alogliptin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin (25 mg/daily)
Trial: 29558784
Drug: Gliclazide extended‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide extended‐release (30 mg/daily for HbA1c 7.5‐8.0% and 60 mg/daily for HbA1c 8.0‐8.5%)
Trial: 20845002
Drug: Flavocoxid (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavocoxid (500 mg twice daily)
Trial: 11146706
Drug: Naproxen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500 mg twice daily)
Trial: 26215702
Drug: G‐Cem Automix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐Cem Automix cement
Trial: 26215702
Drug: G‐Cem Automix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐Cem Automix cement at 37°C
Trial: 1670723
Drug: Intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified chemotherapy
Trial: 12849773
Drug: Executive tasks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Executive tasks administered to children with Klinefelter's syndrome (KS)
Trial: 30150464
Drug: Single i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. doses of 0.1 to 3 mg/kg of body weight
Trial: 30150464
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg q24h over 60 min
Trial: 30150464
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg q12h over 60 min
Trial: 12496225
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (Control)
Trial: 10691270
Drug: Triple regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple regimen (senna syrup, Picolax, Klean Prep)
Trial: 9071429
Drug: Thalidomide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (200 mg/day orally for 28 days)
Trial: 9071429
Drug: Thalidomide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thalidomide (300 mg/day for an additional month)
Trial: 9071429
Drug: Prednisone (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (for the patient who failed thalidomide therapy)
Trial: 20698927
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (placebo)
Trial: 31728618
Drug: CCRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCRT with PG2 injection (Astragalus polysaccharides) administered three times per week
Trial: 31728618
Drug: CCRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCRT with PG2 injection
Trial: 30396454
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist (7-day dosage)
Trial: 30396454
Drug: Long-acting GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting GnRH agonist (single dose)
Trial: 18783399
Drug: Bortezomib 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.0 mg/m²
Trial: 18783399
Drug: Bortezomib 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.3 mg/m²
Trial: 20306195
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses (1.0 and 1.3 mg/m²)
Trial: 16552342
Drug: Ximelagatran 36
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 36 mg orally twice daily
Trial: 16552342
Drug: Warfarin dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0
Trial: 12666712
Drug: Immediate Functional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Functional Loading (IFL) for 422 implants
Trial: 12666712
Drug: Immediate Non-Functional
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Non-Functional Loading (INFL) for 224 implants
Trial: 11967788
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil (AT(1)-receptor blocker)
Trial: 29110675
Drug: Lactoferrin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin and lysozyme daily supplement
Trial: 20191582
Drug: Abatacept (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept (10 mg/kg administered intravenously every 4 weeks)
Trial: 15793107
Drug: micafungin (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: micafungin (12.5 to 200 mg/day)
Trial: 7897962
Drug: prophylactic medication
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prophylactic medication (levobunolol, acetazolamide, apraclonidine)
Trial: 811704
Drug: Cyclandelate (Cyclospasmol),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclandelate (Cyclospasmol), 400 mg four times daily
Trial: 25338498
Drug: rRT+APG101 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rRT+APG101 (400 mg weekly i.v.)
Trial: 17513803
Drug: 13-cis-retinoic acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13-cis-retinoic acid (1 mg/kg/d orally) plus interferon alfa (3 x 10(6) U subcutaneously three times per week)
Trial: 25223173
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no adjuvant therapy)
Trial: 15078261
Drug: Amodiaquine (AQ)
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amodiaquine (AQ) 10 mg/kg
Trial: 15078261
Drug: Artesunate (AR)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate (AR) 4 mg/kg first day then half dose
Trial: 11771678
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (250 mg to 2,000 mg over 10 weeks)
Trial: 7519567
Drug: Chlormadinone acetate
RxNorm normalized name: Chlormadinone acetate
DrugBank: Chlormadinone acetate (DB15903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormadinone acetate (CMA) 25 mg
Trial: 7519567
Drug: Acetazolamide (ACET)
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide (ACET) 250 mg
Trial: 2657616
Drug: Amikacin (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin (800 mg/m2/day) and ticarcillin‐clavulanate
Trial: 2657616
Drug: Vancomycin (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (1.2 g/m2/day), amikacin, and ticarcillin
Trial: 31987235
Drug: Foot reflexology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot reflexology applied twice a week for 6 weeks (30-40 min per session)
Trial: 31500422
Drug: Olanzapine 10
RxNorm normalized name: olanzapine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine 10 mg orally (days 1-4) + ondansetron 8 mg IV + dexamethasone 20 mg IV (30 minutes before chemotherapy) + dexamethasone 10 mg orally (days 1-4)
Trial: 31500422
Drug: Placebo (days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (days 1-4) + ondansetron 8 mg IV + dexamethasone 20 mg IV (30 minutes before chemotherapy) + dexamethasone 10 mg orally (days 1-4)
Trial: 23800177
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination therapy (polypill)
Trial: 22760901
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate IV infusion (2 g)
Trial: 22760901
Drug: Saline IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline IV infusion
Trial: 19953931
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of CD147 expression with depth of prostatic capsule invasion
Trial: 16106594
Drug: Melagatran-ximelagatran (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melagatran-ximelagatran (subcutaneous melagatran for 1-2 days followed by oral ximelagatran for 6-9 days)
Trial: 16106594
Drug: Ximelagatran (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (oral for 7-12 days)
Trial: 12021628
Drug: Itraconazole 100
RxNorm normalized name: itraconazole 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 100 mg/day for 7 days
Trial: 9807036
Drug: Tolrestat 200
RxNorm normalized name: tolrestat 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolrestat 200 mg/day
Trial: 23297711
Drug: Amlodipine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5-10 mg/day)
Trial: 2405556
Drug: Captopril (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25-50 mg twice daily)
Trial: 6212561
Drug: Alcohol-free benzoyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol-free benzoyl peroxide gel
Trial: 31104962
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy initiated within 61 days
Trial: 31104962
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy initiated after 61 days
Trial: 25381429
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) at 375 mg/m² × 4
Trial: 17095924
Drug: PRE-POST group
RxNorm normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRE-POST group (supplement consumed immediately before and after RE)
Trial: 17095924
Drug: MOR-EVE group
RxNorm normalized name: Summer's Eve Medicated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOR-EVE group (supplement consumed in the morning and late evening)
Trial: 16931683
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac (60 mg)
Trial: 8190480
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen (650 mg)
Trial: 8190480
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen (600 mg)
Trial: 28222631
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml US‐TAP block (50 mg bupivacaine + 10 ml saline solution)
Trial: 2669155
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 25 mg/day
Trial: 12351281
Drug: mexiletine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mexiletine 600 mg/d
Trial: 3281307
Drug: Terbutaline 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 0.5 mg (0.5 ml)
Trial: 31298171
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive remediation therapy (CCRT)
Trial: 19117153
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg administered PO
Trial: 19117153
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg administered IM
Trial: 19117153
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg administered IV
Trial: 17006858
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of bromazepam (B3)
Trial: 17006858
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of bromazepam (B6)
Trial: 15029039
Drug: C974P (0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C974P (0.25% fluid carbomer gel)
Trial: 15029039
Drug: C940 (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C940 (conventional carbomer gel)
Trial: 8897086
Drug: Tenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenolol (100 mg)
Trial: 1509999
Drug: Intravenous flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous flecainide (2 mg/kg, maximum dose 150 mg)
Trial: 24275120
Drug: Iron supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplements
Trial: 31800425
Drug: Topical TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical TXA (3.0 g administered 5 minutes before final tourniquet release)
Trial: 31800425
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (1.0 g before tourniquet inflation and again 3 hours later)
Trial: 23892922
Drug: Pegylated G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated G-CSF
Trial: 23892922
Drug: Unpegylated G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unpegylated G-CSF
Trial: 23892922
Drug: Three G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three G-CSF schedules (pegylated and unpegylated)
Trial: 21350110
Drug: Aliskiren (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (150 mg force titrated to 300 mg daily after 3 months) plus losartan (100 mg)
Trial: 31691621
Drug: Cimicifuga racemosa
RxNorm normalized name: CIMICIFUGA RACEMOSA ROOT
DrugBank: Black cohosh (DB13975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimicifuga racemosa (160 mg dry extract with 4 mg of triterpene glycosides)
Trial: 31116919
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow therapy and CPAP
Trial: 19198022
Drug: PEG solution
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG solution and simethicone (Group 2)
Trial: 19198022
Drug: PEG solution
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG solution (Group 1)
Trial: 14719211
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of 2 drugs (rifampicin + cotrimoxazole or doxycycline)
Trial: 14719211
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 3 drugs (streptomycin + rifampicin + doxycycline)
Trial: 14719211
Drug: Treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration of 5 months or less
Trial: 14719211
Drug: Treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration of more than 5 months
Trial: 8821516
Drug: Placebo, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 3 times daily for 7 days